Employees: 1,500
Size Procter & Gamble Health (PGHL.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $979M, the 611th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹5,505 on 18 Nov 2026.
Performance Over six months the shares gained 3.1%, against -14.5% for the median peer and +3.8% for the India market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 13.0% over the last twelve months (peer median +5.7%); the operating margin is 30.8% (peer median 10.5%).
Valuation It trades at 24.5× forward earnings against a peer median of 19.8× (5th most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 86.5 points above its cost of capital (9.9% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹14.1B | ₹14.1B | ₹12.5B | ₹12.3B | ₹11.1B |
| Revenue growth | — | +13% | +1% | +11% | — |
| Gross profit | ₹7.97B | ₹7.03B | ₹6.12B | ₹5.64B | ₹5.08B |
| EBITDA | ₹4.57B | ₹4.64B | ₹4.32B | ₹3.29B | ₹2.71B |
| Net income | ₹3.27B | ₹3.27B | ₹3.13B | ₹2.29B | ₹1.93B |
| Free cash flow | n/a | ₹3.33B | ₹1.67B | ₹2.08B | ₹1.41B |
| Capital expenditure | n/a | ₹155M | ₹85.6M | ₹425M | ₹379M |
| Total debt | ₹72.1M | ₹92.9M | ₹76.2M | ₹120M | ₹28.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PGHL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.2% | -7.6% | 3rd highest of 21 |
| 6-month return | +3.1% | -14.5% | 6th highest of 21 |
| Distance from 52-week high | -21.1% | -38.2% | 4th highest of 21 |
| Revenue growth (TTM) | +13.0% | +5.7% | 8th highest of 19 |
| Operating margin | 30.8% | 10.5% | highest of 19 |
| Forward P/E | 24.5× | 19.8× | 5th most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 5.6% | 7.0% | 6th least demanding of 13 |
| Growth delivered (Del g) | +9.3% | +2.6% | 4th highest of 13 |
| Hurdle (Req g minus delivered) | -3.7 pp | +1.8 pp | 4th least demanding of 13 |
| ROIC minus cost of capital | +86.5 pp | -0.8 pp | highest of 19 |
| EV / EBITDA | 19.3× | 11.1× | 3rd most expensive of 6 |
| Net debt / EBITDA | -0.7× | 2.1× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |